Every Form 4 that Bionano Genomics, Inc. (BNGO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BNGO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BNGO filings page.
Bionano Genomics, Inc. (BNGO) reported that Interim Chief Executive and director Albert Luderer purchased 4,000 shares of common stock on September 4, 2026 in an open market or private transaction. The shares are held indirectly through a Traditional IRA, bringing his indirect holdings in that account to 8,000 shares.
Bionano Genomics, Inc. (BNGO) reported that interim Chief Executive and director Albert Luderer indirectly purchased 4,000 shares of Common Stock on 2026-08-21 in an open-market or private transaction at $1.215 per share. The shares are held indirectly through a Traditional IRA, and this filing does not indicate use of a Rule 10b5-1 trading plan.
Bionano Genomics, Inc. reported that Principal Accounting Officer Mark Adamchak received a grant of 5,000 stock options to buy common stock at an exercise price of $1.12 per share, vesting 50% on each of the first and second anniversaries of the vesting commencement date and expiring on August 2, 2036. This Form 4 replaces an erroneously filed initial Form 3.
Bionano Genomics, Inc. reported that its General Counsel, Jonathan V. Dixon, received a grant of stock options for 15,000 shares of common stock on 2026-08-03. The options have an exercise price of $1.12 per share and expire on 2036-08-02. The award vests 50% on each of the first and second anniversaries of the vesting commencement date, subject to Continuous Service under the company’s 2018 Plan. Following this grant, Dixon holds options covering 15,000 shares. The company also states that this filing replaces an erroneously filed initial Form 3 dated August 5, 2026.
OLDAKOWSKI MARK reported acquisition or exercise transactions in this Form 4 filing.
Bionano Genomics reported a Form 4 for Chief Operating Officer Mark Oldakowski showing a grant of 15,000 stock options to buy common stock at $1.12 per share, expiring in 2036. The options vest 50% on each of the first two anniversaries of the vesting commencement date, subject to continuous service.
Bionano Genomics, Inc. reported an equity award to Chief Scientific Officer Alex Reid Hastie of a stock option covering 54,000 shares of common stock at an exercise price of $1.12 per share, expiring August 2, 2036. Twenty-five percent vests August 2, 2027, with the balance vesting in 36 monthly installments, and the report replaces an earlier erroneous initial ownership statement filed August 5, 2026.
Bionano Genomics, Inc. general counsel Jonathan V. Dixon reported a routine tax-related share withholding. When a restricted stock unit (RSU) award vested on June 3, 2026, the company withheld 24 shares of common stock at $1.30 per share to cover tax obligations. After this non-market disposition, Dixon directly holds 239 common shares.
Bionano Genomics Chief Operating Officer Mark Oldakowski reported a small tax-related share disposition. On June 3, 2026, the company withheld 27 shares of common stock at $1.30 per share to cover his tax obligations on a restricted stock unit (RSU) award that vested the same day. This was not an open-market trade. After the withholding, he directly owns 868 shares of common stock.
Bionano Genomics, Inc. Chief Medical Officer Alka Chaubey reported a routine tax-related share withholding. On shares that vested from a prior restricted stock unit (RSU) award on June 3, 2026, the company withheld 24 shares of common stock at $1.30 per share to cover tax obligations, rather than issuing those shares. After this tax-withholding disposition, Chaubey directly holds 620 shares of Bionano Genomics common stock.
Bionano Genomics, Inc. Principal Accounting Officer Mark Adamchak reported a small, routine tax-related share withholding. On June 3, 2026, the company withheld 7 shares of common stock at $1.30 per share to cover tax obligations when an RSU award vested. After this non-market disposition, Adamchak directly holds 253 shares of common stock.
Bionano Genomics director Aleksandar Rajkovic received a grant of stock options for 9,149 shares of common stock at an exercise price of $1.19 per share. These options vest in equal monthly installments over 12 months and expire on May 13, 2036.
The award is standard equity compensation, not an open‑market stock purchase or sale. The options will be fully vested by the company’s next annual stockholder meeting or upon a qualifying Change of Control, assuming continuous service through each vesting date.
Bionano Genomics, Inc. director Yvonne Linney received a grant of stock options covering 9,149 shares of common stock. The options have an exercise price of $1.19 per share and expire on May 13, 2036.
The award vests in equal monthly installments over 12 months, and will be fully vested by the company’s next annual stockholder meeting, subject to her continuous service. The options also vest in full upon a Change of Control as defined in the company’s 2018 equity incentive plan.
Bionano Genomics director Kristiina Vuori, MD received a new stock option grant. She was awarded options covering 9,149 shares of common stock at an exercise price of $1.19 per share. These options are held directly and represent compensation rather than an open-market purchase.
The options will vest in equal monthly installments over 12 months following the grant date and will in any case be fully vested by the company’s next annual stockholder meeting, so long as her continuous service continues through each vesting date. The award also fully vests upon a Change of Control under the company’s 2018 equity incentive plan, and expires on May 13, 2036 if not exercised.
Bionano Genomics director Christopher J. Twomey received a grant of stock options covering 9,149 shares of common stock at an exercise price of $1.19 per share. These options vest in equal monthly installments over 12 months and will be fully vested by the next annual stockholder meeting or upon a qualifying change of control. Following this grant, he holds options on 9,149 shares that expire on May 13, 2036.
Bionano Genomics director David L. Barker received a new stock option grant as part of his compensation. The award covers 9,149 shares of common stock at an exercise price of $1.19 per share, with no cash paid at grant.
The option vests in equal monthly installments over the 12 months following the grant date and will in any case be fully vested by the date of the company's next annual stockholder meeting, as long as Barker maintains continuous service. The award will also vest in full upon a qualifying Change of Control under the company's 2018 equity incentive plan.
Bionano Genomics, Inc. Chief Medical Officer Alka Chaubey reported a small tax-related share disposition. On the vesting of a restricted stock unit (RSU) award granted on February 15, 2023, the issuer withheld 18 shares of common stock at $1.10 per share to cover tax obligations, leaving Chaubey with 644 directly owned shares.
The Principal Accounting Officer of Bionano Genomics, Inc., Mark Adamchak, reported a small tax-related share disposition. On February 15, 2026, 3 shares of common stock were withheld by the company at $1.10 per share to cover his tax obligations on a restricted stock unit (RSU) award that vested on that date. After this withholding, he directly owned 260 shares. This was an administrative tax-withholding disposition, not an open-market sale.
Bionano Genomics reported an insider equity transaction involving its General Counsel, Jonathan V. Dixon. On February 15, 2026, 6 shares of common stock were withheld by the company to cover tax obligations tied to a restricted stock unit award vesting, at a price of $1.10 per share. After this tax-withholding disposition, Dixon directly owns 263 shares of Bionano Genomics common stock.
Bionano Genomics, Inc. chief operating officer Mark Oldakowski reported an automatic share disposition related to tax withholding. On shares that vested from a restricted stock unit (RSU) award granted on February 15, 2023, the issuer withheld 20 shares of common stock on February 15, 2026 to cover his tax obligations, at an indicated value of $1.10 per share. After this tax-withholding disposition, Oldakowski directly owned 895 shares of Bionano Genomics common stock. This was not an open-market buy or sell order, but a routine settlement mechanism tied to equity compensation.
Bionano Genomics President and CEO R. Erik Holmlin reported a small tax-related share disposition. On the settlement of a restricted stock unit (RSU) award that vested on February 15, 2026, the issuer withheld 51 shares of common stock at $1.10 per share to cover his tax obligations, rather than selling them on the open market. After this withholding transaction, he directly holds 1,657 shares of Bionano Genomics common stock.
Bionano Genomics, Inc. reported an insider equity award to its Principal Accounting Officer, Mark Adamchak. On February 2, 2026, he received a stock option giving him the right to buy 10,890 shares of common stock at an exercise price of $1.27 per share. The option was granted at no cost and is held directly. According to the filing, 100% of the shares subject to the option vest on the one-year anniversary of the grant date, aligning his compensation more closely with the company’s future share performance.
Bionano Genomics reported an insider equity award for its Chief Medical Officer, Alka Chaubey. On 02/02/2026, Chaubey received a stock option to buy 27,737 shares of common stock at an exercise price of $1.27 per share. The option vests monthly over 48 months, beginning on the one-month anniversary of the vesting commencement date, and becomes fully vested and exercisable on the four-year anniversary of that commencement date. Following this grant, Chaubey beneficially owns 27,737 derivative securities directly, and the filing does not report any share sales.
Bionano Genomics chief operating officer Mark Oldakowski received a grant of 27,737 stock options on February 2, 2026. The options give him the right to buy Bionano Genomics common stock at an exercise price of $1.27 per share and expire on February 1, 2036.
The award vests in monthly installments over 48 months, starting one month after the vesting commencement date, so the option becomes fully vested and exercisable on the four-year anniversary of that commencement date. Following this grant, he beneficially owns 27,737 derivative securities directly.
Bionano Genomics, Inc. reported a new equity award for its General Counsel, Jonathan V. Dixon. On 02/02/2026, he received a stock option to buy 26,117 shares of common stock at an exercise price of $1.27 per share. The option vests monthly over 48 months beginning on the one-month anniversary of the vesting commencement date, so it becomes fully vested and exercisable on the four-year anniversary of that date.
Bionano Genomics, Inc. reported that President and CEO, and director, Erik R. Holmlin received a grant of stock options on 02/02/2026. The award covers 69,484 options to buy common stock at an exercise price of $1.27 per share, expiring on 02/01/2036.
The options were awarded at a cost of $0 for the derivative itself and are held directly. They vest monthly over 48 months beginning one month after the vesting commencement date, so the option becomes fully vested and exercisable on the four-year anniversary of that date.